COMP <GO>
RIGL vs UNH // REVENUE GROWTH (YOY)
Rigel Pharmaceuticals Inc. (NASDAQ) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: RIGL 9
— UNH 2
▲ REVENUE GROWTH (YOY) LEADER: RIGL
LAST: $50.53 (-1.52%) • MKT CAP: $943.9M
revenue-growth
64.10%
LAST: $400.44 (-1.60%) • MKT CAP: $359.43B
revenue-growth
3.33%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RIGL VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | RIGL | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 93.30% | 88.31% | +4.99 | RIGL | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 28.20% | 12.38% | +15.82 | RIGL | /roic <GO> |
| EV/EBITDA & P/E Valuation | 7.3x | 15.3x | -7.97 | RIGL | /valuation <GO> |
| Free Cash Flow Yield | 7.87% | 6.25% | +1.62 | RIGL | /fcf-yield <GO> |
| Operating Margin | 42.60% | 5.32% | +37.28 | RIGL | /operating-margins <GO> |
| Net Profit Margin | 68.00% | 3.53% | +64.47 | RIGL | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | 64.10% | 3.33% | +60.77 | RIGL | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.29% | -2.29 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.64 | 3.09 | +0.55 | RIGL | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 7.00% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 58.7 | 55.1 | +3.60 | RIGL | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.33 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 17.7x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $943.9M | $359.43B | -$358.49B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | RIGL REV | UNH REV | RIGL GROSS % | UNH GROSS % | RIGL FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $294.3M | $447.57B | 93.3% | 88.7% | $75.7M | $16.07B |
| FY 2024 | $179.3M | $400.28B | 89.6% | 88.3% | $31.5M | $20.70B |
| FY 2023 | $116.9M | $371.62B | — | 89.6% | -$5.7M | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
RIGL // BETA —
UNH // BETA 0.33